DK145464B - 8-OXAMORPHINAN DERIVATIVES USED AS INTERMEDIATES IN THE PREPARATION OF N-SUBSTITUTED 3-HYDROXY-8-OXAMORPHINANES - Google Patents

Description

(19) DENMARK (wj

® (η; PRESENTATION WRITING OR 1U5464B

DIRECTORATE OF THE PATENT AND TRADEMARKET SYSTEM

(21) Application No. 2063/79 (51) JntCI.3 C 07 D 491/08 (22) Filing day 1 8 May 1979 (24) Race day 17 · Jul. 1974 (41) Aim. available May 18, 1979 (44) Presented Nov. 22; 1982 (86) International application no. - (86) International filing day (85) Continuation day - (62) Common application no. 3838/74

(30) Priority 18 Jul. 1973, 38051 5, US

(71) Applicant BRISTOL-MYERS COMPANY, New York, US.

(72) Inventor Ivo Monkovic, CA: Yvon Lambert, CA.

(74) Representative 7¾. Qstenfeld Patent Office A / s.

(54) 8-oxamorphinan derivatives for use as intermediates in the preparation of N-sub = substituted 3-hydroxy-8-oxamor = -phlanes.

The present invention relates to novel 8-oxamorphinan derivatives for use as intermediates in the preparation of certain N-substituted 3-hydroxy-8-oxamorphinans, which end products are useful as analgesics and / or narcotic antagonists, especially as neuroleptic analgesics.

The intermediates in question are characterized in that they have P in the general formula: wherein R represents alkyl of 1-6 carbon atoms and R represents H or alkyl of 1-6 carbon atoms, or are acid addition salts thereof.

2

14546A

The end products in question are compounds of the formula jqXX "" ° k) wherein R ^ represents, g -CH 2 ~ <3 ~ or -CH₂, where H or CH₂, and R ^ represents 6 carbon atoms, or pharmaceutically useful acid addition salts thereof.

The end products in question have the oxamorphinan basic nucleus, which can be indicated by the following formula with numbered positions.

—R1 (C.3J ClT i-4'r3 / Tv'j H0 4; j> 8 6

Although there are three asymmetric carbon atoms marked with stars in the oxamorphinan molecule below, only two diastereoisomeric (racemic) forms are possible because the iminoethane system linked to positions 13 and 9 is geometrically bound to a cis (1,3-diaxial) ring. Therefore, these racemates can only differ with respect to the configuration of the carbon atom at the 14-position. The only variable will be that the substituent at the 14 position may be in the cis and trans positions relative to the iminoethane system. When the alkyl substituent at the 14-position of the compounds of the present invention is in a trans position relative to the iminoethane system, these are 14ct-alkyloxaiso-morphinans. When the alkyl substituent at the 14-position is in the cis position relative to the iminoethane system, these are 143-alkyloxamorphinans.

The graphical indications of oxamorphinans are intended to include the dl racemic mixtures, as well as the individual d and 1 isomers thereof.

The U5464 3 14α and 14β alkyloxamorphinans can exist as two optical isomers, namely as the left and right rotating isomers. The optical isomers can be graphically represented as follows: 14β-alkyloxamorphinane: 14 · 14α-alkyloxaisomorphinane: 11 ° OC;

U U

From the specification of Danish Patent No. 141,624, it is known that certain N-substituted 14-hydroxy-morphinan derivatives are useful as analgesics and / or narcotic antagonists. The N-substituted 3-hydroxy-8-oxamorphinans produced by the 8-oxamorphinane derivatives of the present invention have similar effects, but have also been found to have a greater degree of depressive or sedative activity, so that in contrast to the known compounds can be used as neuroleptic analgesics.

The conversion of the 8-oxamorphinane derivatives of the invention to the N-substituted 3-hydroxy-8-oxamorphinans or acid addition salts thereof is accomplished by A. treating a compound of formula '2' wherein R represents alkyl of 1-6 carbon atoms and R has the meaning given above, with an alkylating or acylating agent of the formula 4 U5464 X - (Z) - w

where W represents <R ^ or τ <Τ · where H represents

? or CH 2, Z represents carbonyl (-C-) or -CH 2 - / and X represents chlorine, bromine or solute, in an inert organic solvent in the presence of a suitable base to prepare a compound of formula -

wherein R Z, W and R have the meaning given above and when Z

0 represents carbonyl (-C-), B. treats compound (III) with lithium aluminum hydride in an organic solvent to form a compound of the formula.

-Mf,

kJ

Wherein R, W and R are as defined above, and C. cleaves the ether function of compound (ΠΙΙ) or (EV) by treatment with an agent in the form of NaS-3Hg, hydrobromic acid, boron tribromide or pyridine hydrochloride, after which the product prepared, if desired, is converted into a pharmaceutically useful acid addition salt thereof.

With the intermediates of the invention, all the isomers, including the optical isomers in their individual form, can be prepared.

The optical isomers can be separated and isolated by fractional crystallization of the formed diastereoisomeric salts, e.g. with d- or 1-tartaric acid or D- (+) - α-bromo-camphor sulfonic acid. The reversible isomers of the compounds of the invention are preferred. Other acids commonly used to isolate isomers can be used.

The term "pharmaceutically useful acid addition salt" encompasses all the inorganic and organic acid salts of the compounds of the invention, which are of the kind commonly used to prepare non-toxic salts of pharmaceutically active agents containing amine functions. Examples include such salts formed by mixing the compounds of Formula I with hydrochloric, sulfuric, nitric, phosphoric, phosphoric, hydrobromic, maleic, malic, ascorbic, citric, tartaric, pamoic, lauric, stearic, palmitic, , acidic lauryl sulphate, napthalin sulphonic acid, linoleic acid, linolenic acid or fumaric acid. '

The term "inert organic solvent" herein means an organic solvent which does not participate in the reaction in the sense that it remains unchanged when the reaction is completed. Such solvents are methylene chloride, chloroform, dichloroethane, tetrachloromethane, benzene, toluene, ether, ethyl acetate, xylene, tetrahydrofuran, dioxane, dimethylacetamide, dimethylformamide and the like when an acid halide is used. In the case of an alkylation reaction, the inert solvent may also comprise lower alkanols such as methanol, ethanol-n-propanol and iso-propanol.

The intermediates of the invention are prepared by Hian A. hydrating the compound of formula - r4 {vii)

Ru γ OH

Wherein R 4, r and R have the meaning given above, B. sulfonates compound VIII with a large excess of a (lower) alkyl or arylsulfonyl halide to form the compound of the formula.

R 2 O · OH

'IX

wherein R, R and R'4 are as defined above and Z represents (lower) alkyl or aryl, C. terminates compound IX by treatment with an excess of sodium hydride to form the compound with the formula

U

wherein R 4, R 2 and R 2 have the meaning given above, D. treats compounds X with cyano bromide to form the compound of formula R 2 o '0 u 9 3 wherein R and R have the meaning given above and 7 treats E. compound 3fl with lithite aluminum hydride in an inert solvent to form a compound of formula II. "Preferred compounds are of formula r 20 (Up) 2 3 'where R is methyl and R is H or alkyl of 1-6 carbon atoms, or are acid addition salts thereof, which are prepared by A. hydrating the compound of formula 2 (VIIP) RO, where R 1 and R 2 represent methyl, and R 2 represents H or alkyl of 1-6 carbon atoms, by treatment with an excess of borane, a slight excess of an alkali metal hydroxide (sodium hydroxide) and hydrogen peroxide to form of the compound of formula R4

ix ^ H2OH

4 2 3 wherein R, R and R have the meaning given above. B. sulfonates compound VIIIIIIp with a large excess of a (lower) alkyl or arylsulfonyl halide to form the compound of formula

2 IX P

ro; OH

! s ^^ PH20S02 Z

Wherein R, R and R have the meaning given above and Z represents (Lower) alkyl or aryl, C. terminates compound IXp by treatment with an excess of sodium hydride in an inert organic solvent (benzene, toluene, xylene or the like). ) to form the compound of formula xp R20 u O · 3 where R 2, R and R have the meaning given above, D. processes compound: ¾) with cyanobromide to form the compound of formula, m - u 2 3 where R and R have the meaning given above, and E. treats compound XIp with lithium aluminum hydride in an inert solvent to give compound of formula (IIp) f and then, if desired, converts the product into an acid addition salt thereof.

: ---. 3 145464 9

Other preferred compounds have the formula kN - H (IIz) 2 2ΘΘζΕ 2 where R represents methyl and R represents H or alkyl of 1-6 carbon atoms, or are acid addition salts thereof, which are prepared by substituting A hydrates the compound of formula 4 2 3 wherein R and R represent methyl and R represents H or alkyl of 1-6 carbon atoms, by treatment with an excess of boron, small excess of an alkali metal hydroxide (sodium hydroxide) and hydrogen peroxide to form the compound of the formula - 'rf

R20 / kx ^ JSV> 0H

Wherein R, R and R have the meaning given above, B. sulfonates compound VIIIz with a large excess of a (lower) alkyl or arylsulfonyl halide to form the compound of formula U5464 or IXz R10; wherein R 1, R 2 and R 3 have the meaning given above, and 2 represents (lower) alkyl or aryl, C. terminates compound IXz When treated with an excess of sodium anhydride in an inert organic solvent (benzene, toluene, xylene or the like) to forming the compound of formula χζ r10 / 'V ^ 7 |) where rA R and R are as defined above, D. processes compound Xz with cyanobromide to form the compound of formula

n - CN

where R and R have the meaning given above, and 2 E. treat compound Xiz with lithium aluminum hydride in an inert solvent to form the compound of formula (IIz) and, if desired, convert the product to an acid addition salt thereof.

3

It is well known from the art that it is possible for some compounds to possess both agonistic and antagonistic properties. An agonist is a compound that is similar to a narcotic analgesic and possesses analgesic properties. An antagonist is a compound that counteracts the analgesic and euphoric properties of a narcotic analgesic. It is possible for a foot pleasure to have both properties. A good example of such a compound is cyclazocin.

"a; · n 145464

The compounds herein referred to as 15 C (racemic mixture), d-15C (right-turn isomer), 1-15C (left-turn isomer) and dl-15e (see examples of structure) and the compound called l-BC -3261 was tested in vivo to determine their agonistic and / or antagonistic properties. The results of the studies are shown in Table I. The figures given are the number of mg / kg body weight of the compound which produces an agonistic or antagonistic effect in 50% (denoted by ED, -g) of the mice or rats participating in the experiment.

CXf & l 14546Λ 12 ^ Η Η ω οο 6 - ιι

W C CO CO

• Η (U II

C ft C C

Ο Ιί -Η · Η εγ> η o o (8>. · TNHVD 0 Ο

4-ι cn roQroQin- · - * · N N

EDO '' v ·> N ci N - A (0

(8 H CM Ι- ^ νθ3ιη ° 0 {ΝΗ CO CN N N

«E a

5® HI-VO

ι + ι +> mots cntNooco 2! "I I

M +> OCMOCTiO'HO oo nn å «W 0A000 HOO OO ό 0 § g ro · · m · · v *" 1 ^ 5 C QQCM QQ «8 *« tO g, 0) no · · -. O - "- gc

XJCMZZHZZ ° 'inu' 'CMO f I

Oj (1) co vo vo · H cnOOOCM M ™ 'J0 ™> 1 u nQOOoo ^ vnrn H ° - --1 OSWOZOHOHOO OO ^ _ £

C

a) a) -p ε cn <u · · vo · σ> ^ d h CHao-a ^ '' '' * _ · η ό

OnJO · • «a1 · r— covovo -q-M T I

XI X5 CM 2ΐΖΗΖΗΗ '\ Μ' (NH ^ H

Qj I I «Η

Cn u Si »µ *

k * 0 d *> <I ^ D

Η \ E «Η O> i> ° -8 · σι -C I

CJC> i +1 VO H CM Ol'HCN 00 H .µ 0C

h g x +> υ ~ 21 '™' * oo 'a> ϋ o

aj ocncno o nr ο η η o oo g OS

Λ row I> 1 -Η ιβ σ _________ 1 η Λ Λ Ε-4 m --- .... . w <8 Ο.

Q ο Q ro Q <Ν ODD Ω Q ro So η2 «3> ΖΗΖηΖΖΖ ZZ, 4" ίο ϋι ω ft>, νο ο C -p il .C - d

η -Ο σι + i m S

CO mincNHo ·· · '' o -X

Ό (K ohoooQQQ QQ g -crO

O W o * o o o ZZZ ZZ ig ¢ 300¾> ff i (8 -> t * H C <N Xl

C Ln H -H * I

o · * · <Μ · ·. Λ ι-l «C Q Q I- Q O Q OQ ιοα, ΙΗ • HO · · · µ · *. ^ ΙΠ · - ·. µ ^ i PCMZSOMSomHZ O'Z Q oho σ c g> 1 m H - o> 1 ί fl>> n ro ^ S Ϊ2> -, x 4->

Cd <noHi — H C 'm tf C <»o« x! d) S HrrHoo or- ή in O <=> -¾ µ j h £ O ........ VOHHO, 'o H rg g -3 0.WO o o O -3-OCNMteWOrJ · 0C> lHl

«« U X H S> 1 CO

M I X! I Q <'ioOjCOOI— - Jh I Η 1

in O H Øi H

- g> 1 O> 1

rj * Η Η Η H

- H O H

Γ0 H 18> 1 IB

O - H I O I

w m 18 z - Z

H o -I - I I

<“+ J C ΗΖΗΓ0Η T3 Λ5 td jrt 5 rrj CXIUMH ™. n 2

.4 (8-0 +) 18 C ~ Λ C

xacoos-iHHCft t! <u 0-0 (8 (8 -O vo OHO Οφ 00-O + iOcnOXO o c iwie iflroNp4H Ϊ9 ιΒΛΟΌΦ

<U-000 +> l 18 0 Η (8X

> min 0- ^ 0 (8 H0 Ό o Η H <L) CQ CH> u, 2

Oiniimi onjqj £ _ ^ i-l'dHHH ftZH_U Z_ 13 U54B4

All compounds were tested as tartrates, but the weights given in mg / kg are correct and refer to the free base.

A 50% reduction in the number of phenylquinone-induced torsions (Siegmund, E.A. et al., Proc. Soc. Biol. Med. 95,729, 1957).

2

Antagonism to Straub tail induced by oxymorphone (2 mg / kg sc) in 50% of mice.

3

Antagonism against loss of directional reflex induced by oxymorphone (1.5 mg / kg sc) in 50% of rats.

4

A 50% reduction in the analgesic effect induced by morphine (15 mg / kg sc) as measured by the rat tail virus method (Harris, L.S. and Pierson, A.K., J. Pharmacol. & Expt. Therap., 143, 141, 1964).

^ N.d. - does not mean made

It is clear from the table that compounds l-15c and l-BC-3261 exhibit strong agonistic and antagonistic activity in parenteral and oral administration. All of the compounds in question have varying degrees of potency with respect to the effects in question.

As is the case with most of the compounds of this type, the compounds of the invention have some minor anti-tussive effect.

The normal, oral and parenteral doses of the subject compounds are in the adult range of about 0.1 to approx. 50 mg three to four times a day depending on the route of administration and the particular compound administered.

It is stated in the literature that the compound haloperidol, 4 [4- (p-chlorophenyl) -4-hydroxypiperidino] -4'-fluorobutyrophenone (Merck Index, 8th edition, page 515), has found some experimental use to relieve withdrawal symptoms in drug addiction. Therefore, it is possible to combine haloperidol with the narcotic antagonists prepared from the invention to produce a product which not only counteracts drug addiction but can also be used for treatment therapy in the absence of opiates.

Haloperidol is usually administered orally in an amount of 0.5 - 5.0 mg two or three times daily depending on the severity of the disease. A dose of ha LoperidoL in this interval would be administered simultaneously with an effective dose of the narcotic antagonist to produce the desired result.

Other combinations may include the narcotic antagonists along with sedatives such as chlorine diazepoxide and diazepam or: phenothiazines such as chlorpromazine, promazine or methotrimeptrazine.

14 U5464

Preparation of intermediates according to the invention 3,4-dihydro-7-methoxy-1-allyl-2 (1H) naphthalenone (2a)

To a stirred solution of 50 g (0.284 mol) of 3,4-dihydro-7-methoxy-2 (1H) naphthalenone dissolved in 200 ml of dry benzene was added over 5-10 minutes and under nitrogen 40.5 g (0 (5 moles) of pyrrolidine dissolved in 50 ml of benzene. The mixture was refluxed for 1 hour and 5 ml of water was collected in a Dean-Stark apparatus. The mixture was cooled and slowly added to 60.5 g (0.5 mole) of allyl bromide dissolved in 300 ml of benzene. The resulting mixture was refluxed for three hours. Then 200 ml of water was added to the reaction mixture and the reflux resumed. After 30 minutes, the mixture was cooled, the benzene layer was separated, washed with water, followed by water saturated with sodium chloride, dried over sodium sulfate and evaporated to dryness. The residue was distilled to give 52.20 g (85% yield) of compound 2a; mp 106-112 ° / 0.01-0.05 mm. The IR and NMR spectra were consistent with the structure.

Analysis calculated for C, 77.74; H, 7.45.

Found: C, 77.47; H, 7.50.

3,4-dihydro-7-methoxy-1-allyl-1- (2-dimethylaminoethyl) -2 (1H) -naphthalenone hydrobromide (3a)

jgfX

CH30 jCx ^ CH3. HBr -J \ 3

A mixture of 400 ml of dry benzene, 22 g (0.25 mol) of tert-amyl alcohol and 10.62 g (0.25 mol) of sodium hydride was refluxed under nitrogen for 30 minutes or until all the hydride was consumed. Then, 47.2 g (0.22 mol) of compound 2a in 100 ml of benzene was added slowly while distilling off the excess amyl alcohol. An additional 100 ml of benzene was added and distilled off. Then, 28 g (0.3 mole) of 2-chloro-N, N-dimethylaminoethane was added dropwise in 100 ml of benzene. The reaction mixture was refluxed for 20 hours, washed twice with water and diluted with ether and extracted with 1N HCl. The acidic extract was heated to 60 ° C for 1 hour, cooled and extracted with ether to recover 15 g of compound 2a. The acidic extract was then cooled, basified with NH 2 OH and extracted with ether. It was dried over potassium carbonate, treated with charcoal and, after filtration, with dry hydrocarbon.

33.87 g (61.5%) of the HBr salt of compound 3a were obtained. After recrystallization from methanol / ether, the salt melted at 139-140 °. The IR and NMR spectra were consistent with the structure.

Analysis calculated for cigH25NO2'H +: C, 58.69} H, 7.11} N, 3.80.

Found C, 58.63} H, 7.16} N, 3.59.

n.r - 3-Bromo-3,4-dihydro-7-methoxy-1-allyl-1- (2-dimethylaminoethyl) -2- (1H) naphthalenone hydrobromide (4a)

To a stirred solution of 15 g (41 mmol) of compound 3 a in 100 ml of methylene chloride and 300 ml of tetrahydrofuran (THF) in the dark was added 20.58 g (41.5 mmol) of pyrrolidone hydrotribromide in 300 ml of THF over a period of 4 hours. After the addition, the reaction mixture was allowed to stand overnight at room temperature. The solution was evaporated to dryness and the solid residue was recrystallized from 700 ml of isopropanol to give 12.7 g (68.5%) of compound 4¾, mp 149-150 ° C. The IR and NMR spectra were consistent with the structure.

Calcd. For C NO NOH NO NONoHr.HDr: C, 48, 4}, 5,6)} N, 3.13.

Found: C, 48.64; II, 5.70; N, 3.14.

2-Methoxy-2-methyl-5-allyl-9-oxo-6,7-bonzomorphanmothobromide (5a) 4 * / C, the salt of compound 4a (12.6 g, 0.028 mol) was dissolved in ice-cold water , placed in a separatory funnel and covered with ether. Enough concentrated ammonium hydroxide was added to make the mixture alkaline, and the free base of compound 4a was extracted and separated as quickly as possible. The ether was evaporated and the residue dissolved in acetone and allowed to stand overnight. 6.55 g (65.5% yield) of compound 5a was obtained in solid form. After recrystallization from iso-propanol, the compound melted at 175-177 ° C. The IR and NMR spectra were consistent with the structure.

Analysis calculated for C ^ IHNNC₂CH₂Br. 1/21 O: C, 57.60; H, 6.71; N, 3.73.

Found: C, 57.44; H, 6.78; N, 3.58.

2'-methoxy-2-methyl-5-allyl-9-oxo-6,7-benzomorphan (16a)

A suspension of 2 g (5.46 mmol) of compound Va in 25 ml of 1-octanol was heated under reflux and nitrogen atmosphere for 15 minutes.

After cooling, the mixture was poured into 40 ml of 0.5N hydrochloric acid and extracted twice with 100 ml of petroleum ether to remove octanol. The aqueous layer was basified with aqueous ammonia and the free base extracted with benzene to give 1.23 g of an oil 16a after drying and evaporating the solvent. The oil was stirred with a solution of 350 mg oxalic acid in 5 ml of water for 1 hour and allowed to stand at 5 ° for 16 hours. Separated solid was filtered off to give 980 mg (47%) of compound 16a oxalate containing one mole of crystallization water; mp 156-162 ° C. The product recrystallized from water melted at 160-161 ° C under roof of water at 110 ° C.

Analysis calculated for ^ 7 ^ 21 ^ 2 ^ 2 ^ 2 ^ 2 ° 5 C, 60.15; H, 6.64; N, 3.69.

Found: C, 60.52; H, 6.72; N, 3.70.

The IR and NMR spectra were consistent with the structure.

5-Allyl-2L-methoxy-2,9-dimethyl-9α-hydroxyl-6,7-benzomorphan (7b, 7c)

Petroleum ether i6a

! OH

. "D 7C

A solution of methyl lithium in ether (71 ml of a 5% solution, 115 mmol) was transferred with a syringe to a 2-liter flask under nitrogen, evaporated to dryness and covered with 500 ml of dry petroleum ether. To the violently stirred suspension thus obtained (below N 2) was added dropwise a solution of 14.60 g (53.8 mmol) of compound 16a in 25.0 ml of dry petroleum ether (30-65). The reaction mixture was then stirred at 1 in. 20-25 ° for L9 hours. A solution of methyl lithium in ether (15 ml of a 5% solution, 24 mmol) was added and the mixture was stirred for 1.5 hours to complete the reaction. Water was added slowly to destroy the excess methyl lithium and the organic phase was washed with water.

The aqueous phase was extracted with ether, dried over sodium sulfate and evaporated to dryness to give 14.51 g (93%) of an oil which was a mixture of Compound 7b (40%) and 7c (50% (estimated by NMR) The NMR spectrum showed two clear signals for CH 2 - <J - OH at {= 1.0 (II) and i = 1.58 (III) based on TMS (tetramethylsilane).

After treatment with charcoal, the free base (13.05 g) was dissolved in 90 ml of 95% ethanol and added to a boiling solution of 11.96 g of picric acid in 150 ml of 95% ethanol.

18 U5464

The solution was kept at 5 ° for 60 hours and filtered off 21.88 g of a yellow solid which was a mixture of compounds 7b and 7c (20:80). Two recrystallizations from dioxane and 95% ethanol gave 15.3 g (58%) of the α-isomer 7c; mp 209-12 °.

Treatment of the free base with oxalic acid in methanol and ether gave a solid which, after recrystallization, gave an analytical sample, mp 208-209 ° (7c).

Analysis calculated for C18H25NO2.C2H2O4. ^ 63f78. Hf 7f21. N, 3f71.

Found! C, 63.78; H, 7.41; N, 3.92.

The mother liquor was concentrated and 6.16 g (24%) of the β-isomer 7b crystallized. Recrystallization from acetone ether gave a sample melting at 175-8 °. The IR and NMR spectra were consistent with the structure.

9a-Hydroxy-2'-methoxy-2,9β-dimethyl-5- (propane-3-01) -6,7-benzomorphane (8c) @ 3? cll5c ^ P

To a cooled (-10 °, ice bath) solution of 0.69 g (2.4 mmol) of compound 7c in 24 ml of tetrahydrofuran was added 9.6 ml (9.6 mmol) of a 1M solution of borane in tetrahydrofuran. After 4 hours, 10 ml of a 1N solution of sodium hydroxide (dropwise with respect to the first 0.5 ml) and 1.26 g (10.0 mmol) of a 30% solution of hydrogen peroxide were added. After stirring for 1 hour at 20-25 °, the solution was acidified with 20 ml of 1N hydrochloric acid, maintained at 20-25 ° for 0.5 hour and refluxed for 1 hour. The solvent was then evaporated in vacuo and the residue was dissolved in dilute ammonium hydroxide and extracted with methylene chloride (4 x 100 ml). The extracts were washed with water, dried (Na 2 SO 4) and evaporated to dryness to give 0.77 g of on oil which crystallized from benzene to give 0.61 q (83%). A sample obtained from tetrahydrofuran petroleum ether melted vod 152-4 ° (dc).

Analysis calculated for C18 H27 NO3: C, 70.79; H, 8.91; N-, 4.59.

Found: C, 71.17; H, 9.04; N, 4.44.

The IR and NMR spectra were consistent with the structure.

V 'a' "* ψ" 19 USiSi 3-methoxy-14g-methyl-N-methyl-8-oxamorphinane (10c) ch3 °

To a solution of 1.38 g (4.5 mmol) of compound (8c) in 50 ml of tetrahydrofuran and 5 ml of pyridine was added 1.76 ml (2.59 g, 22.5 mmol) of mesyl chloride. After stirring for 3 hours at 20 °, the solvent was evaporated in vacuo, then the oily residue was dissolved in dilute hydrochloric acid and extracted with ether. The aqueous phase was made basic with ammonium hydroxide and extracted with methylene chloride. The methylene chloride extracts were washed with water, dried (Na 2 O 4) and evaporated in vacuo to give 1.89 g of a brown oil. The crude oil thus obtained was dissolved in 30 ml of dry dimethylformamide, placed in a flask under nitrogen, cooled to 0 ° C (ice-salt bath) and treated with 0.43 g (9.0 mmol) of a 57% dispersion of sodium hydride in mineral oil washed twice with benzene. The cold bath was removed and the reaction mixture was stirred at 0 for 16 hours. The solution was cooled and the excess sodium hydride was destroyed by careful addition of water. The solvent was evaporated in vacuo to give a semi-solid residue, dissolved in water, basified with ammonium hydroxide and extracted with methylene chloride. The organic extracts were washed with water, dried (Na 2 SO 4) and evaporated in vacuo to give 1.28 g of a brown oil. Dry column chromatography of the residue on an alumina column using chloroform as the eluent afforded 0.98 g (76%) of the pure compound 10c. The hydrochloride salt was recrystallized from methanol-ether to give a sample melting at 242-44 °.

Analysis calculated for C C ^ g g gClClCl C, 66.76; H, 8.09; N, 4.33.

Found: C, 66.35; H, 7.93; N, 4.12.

The IR and NMR spectra were consistent with the structure. N-cyano-3-methoxy-14β-methyl-8-oxamorphinane (11c)

/ VCN

mk

a «3 ° i ^ J

145464 20

A solution of 0.17 g (1.6 nunol) cyanobromide in 5 ml of chloroform was added dropwise to a solution of 0.38 g (1.3 mmol) of compound 10c in 5 ml of chloroform. After refluxing for 22 hours, the solvent was evaporated in vacuo and the oily residue crystallized from methanol to give 0.25 g (64%). The mother liquor was chromatographed on a column of silica gel. Elution with chloroform and 2.5% methanol-chloroform afforded 0.13 g (33%) of compound 11c. An analytical sample, mp 157-8 °, was recrystallized from methanol.

Analysis calculated for c1gl * 22N2 ° 2: C '7.43; N, 0.39.

Pound: C, 72.45; H, 7.50; N, 9.35.

The IR and NMR spectra were consistent with the structure.

3-methoxy-148-methyl-8-oxamorphinane (12c)

A solution of 0.60 g (2 mmol) of compound ILc in 15 ml of dry tetrahydrofuran was slowly added to a cooled (0 °) and stirred solution of 0.30 g (8 mmol) of lithium aluminum hydride in 30 ml of tetrahydrofuran under nitrogen. The reaction mixture was stirred at 0 ° C for 15 minutes, gradually heated and refluxed for 3 hours. After cooling to 0 °, 0.3 ml of water, 0.22 ml of 20% sodium hydroxide and 1.05 ml of water were added successively. The reaction mixture was stirred at 20 ° for 20 minutes, then the solid was filtered off and the filtrate evaporated to dryness to give 0.69 g of an oil which crystallized as an acctone ether hydrochloride salt to give 0.50 g (80%). Recrystallization from methanol-ether afforded an analytical sample with a melting point of 270 ° (dec).

Calcd for C 18 H 24 ClNO 2: C, 65.90; H, 7.81; 4.52.

Found: C, 65.46; H, 7.80; N, 4.52.

The IR and NMR spectra were consistent with the structure.

21 145464

The conversion of intermediates into valuable end products is illustrated in more detail in the following examples:, r. ';

Example 1 N-cyclopropylcarbonyl-3-methoxy-143-methyl-8-oxamorphilane (13c) ::

A solution of 0.532 g (5.08 mmol) of cyclopropylcarboxylic acid chloride in 25 ml of methylene chloride was added to a cooled (0 °, ice bath) solution of 1.39 g (5.08 mmol) of compound 12c in 50 ml of methylene chloride and 1.0 ml. triethylamine. After 1 hour at 0 °, the reaction mixture was diluted with 300 ml of methylene chloride, washed with 1N hydrochloric acid and water. The organic fraction was dried (Na 2 SO 4) and evaporated in vacuo to give 1.97 g of an oil which crystallized from ether-petroleum ether to give 0.33 g (19%). The mother liquor was chromatographed on an alumina column. Chloroform elution gave 0.93 g (53%) of the amide 13c. An analytical J sample obtained by recrystallization from ether-petroleum ether had a melting point of 141-3 °.

Analysis calculated for C 21 H 27 NO 3: C, 73.87; H, 7.97; tt, 4.10.

Found: C, 73.56; H, 8.03; N, 3.91.

The IR and NMR spectra were consistent with the structure. N-cyclopropylmethyl-3-methoxy-143-methyl-8-oxamorphinane (14c).

'island

To a cooled (ice-salt bath) and stirred solution of 152 mg (4.0 ranol) of 1 L lithium aluminum hydride in 40 ml of dry tetrahydrofuran was slowly added a solution of 0.69 g (2.0 mmol) of compound 13c for 20 min. The reaction mixture was refluxed for 2 hours, cooled in an ice bath, and the excess hydride was destroyed with 0.15 ml of water, 0.11.

U5464 22 ml of 20% sodium hydroxide and 0.53 ml of water. The solid was filtered off and the solvent evaporated in vacuo to give 0.76 g of a colorless oil which crystallized as the hydrochloride salt from methanol ether to give 0.71 g (97%) of compound 14c. Recrystallization gave a sample melting at 246-7 °.

Analysis calculated for C 21 H 30 ClNO 2: C, 69.31; H, 8.31; N, 3.85.

found; C, 69.24; H, 8.55; N, 3.75.

The IR and NMR spectra were consistent with the structure.

N-cyclopropylmethyl-O-hydroxy-β-methyl-S-oxamorphinane (15c)

KJ

To a cooled (ice-bath) suspension of 550 mg (13 mmol) of a 57% dispersion of sodium hydride in mineral oil previously washed twice with benzene in 15 ml of dry dimethylformamide under nitrogen was added 1.05 ml, 887 mg (14). mmol) ethanthiol. The suspension gradually became a clear solution. To the solution thus obtained was added 424 mg (1.3 mmol) of compound 14c in 5 ml of dry dimethylformamide and the reaction mixture was gently refluxed for 3 hours. After cooling, the solution is poured onto 250 ml of ice and water, then the pH is adjusted to approx. 8 with dilute hydrochloric acid and the aqueous phase is extracted with methylene chloride (4 x 100 ml). The extracts were dried (Na 2 SO 4) and evaporated in vacuo (0.4 mm Hg / 40 ° C) for 30 minutes to give 458 mg of an oil which was chromatographed dry on an alumina column.

Chloroform elution gave 323 mg (79%) of the phenol 15c. Crystallization of the hydrochloric acid salt from methanol-ether-hydrogen chloride gave a sample which melted at 268-70 °.

Analysis calculated for C20 H28 Cl2 NO2: C, 68.65; H, 8.07; N, 4.00.

found; C, 68.81; H, 8.24; N, 3.79.

The IR and NMR spectra were consistent with the structure.

Example 2 N-cyclobutylcarbony1-3-me thoxy-14 β-me thy1-8-oxamorphi nan (13e)

A solution of 1.37 g (11 mmol) of cyclobutylcarboxylic acid chloride in 20 ml of methylene chloride was added to a cold (0 °, ice bath) solution of 2.86 g (10 mmol) of compound 12c in 30 ml of dry methylene chloride and 1.66 ml U5464 (1.21 g, 12 mmol) of triethylamine. The reaction mixture was allowed to stand for 20 minutes at room temperature, diluted with 250 ml of methylene chloride, 1 washed with 1N hydrochloric acid, water, 1N sodium hydroxide and water. The organic phase was dried (Na 2 SO 4) and evaporated in vacuo to give 3.43 g (93%) of compound 13e. The analytical sample was crystallized from ether; mp 166-7 °. The IR and NMR spectra were consistent with the structure.

Analysis calculated for C 22 H 29 NO 3: C / 74'33 '8.22j N, 3.94.

Found C, 74.27; H, 8.25; N, 3.92.

N-cyclobutylmethyl-3-methoxy-148-methyl-8-oxamorphinane (14e)

A solution of 3.43 g (9.7 mmol) of compound 13e in 50 ml of dry tetrahydrofuran was added dropwise (10 minutes) to a stirred solution of 0.74 g (19 mmol) of lithium aluminum hydride in 50 ml of tetrahydrofuran. The reaction mixture was gradually heated and refluxed for 30 minutes. Then the mixture was cooled (0 °, ice bath) and the excess hydride was destroyed with 0.74 ml of water, 0.55 ml of 20% sodium hydroxide and 2.6 ml of water. The solid was filtered off and the solvent was evaporated in vacuo to give 3.13 g of an oil which crystallized from absolute ethanol to give 0.93 g (28%) of compound 14e. The mother liquor was chromatographed over alumina (dry column chromatography).

Elution with benzene afforded 1.03 g (31%) of compound 14e. An analytical sample, mp 105-7 ° was recrystallized from absolute ethanol. The IR and NMR spectra were consistent with the structure.

Analysis calculated for C 22 H 3 NO 2: C, 77.38; H, 9.15; N, 4.10.

Found: C, 77.84; H, 9.23; N, 4.09.

N-cyclobutyl-methyl-3-hydroxy-14B-methyl-8-oxamorphinane (15e)

To a suspension of 1.33 g (32 mmol) of about 57% dispersion of sodium hydride in mineral oil (washed two qango against benzene), in 25 ml of dimethyl formamide cooled in an ice bath and under nitrogen was added dropwise 2.35 ml (32 mmol ethanethiol. The cold bath was removed and the reaction mixture was stirred at 20-25 ° until a clear solution (15 minutes) was obtained. To the solution thus obtained was added a solution of 0.93 g (2.7 mmol) in 10 ml of dimethyl formamide and the reaction mixture was gently refluxed (153-6 °) for 2 hours.

The cooled mixture was poured into dilute hydrochloric acid, basified with concentrated ammonia and extracted with methylene chloride.

The organic layer was extracted with 1N hydrochloric acid and the aqueous extracts were made basic with concentrated ammonia and extracted with methylene chloride. The organic phase was dried (Na 2 SO 4), treated with charcoal and evaporated in vacuo to give 1.05 g of an oil. The oil 24 was chromatographed over 75 g of silica gel (dry column chromatography). Elution with 100 ml of chloroform followed by ether gave 0.70 g (78%) of compound 15e. The oxalate salt was prepared from methanol-ether. The IR and NMR spectra were consistent with the structure. Recrystallization of the oxalate from ethanol gave a sample melting at 130-132 °.

Analysis calculated for C21H29NO2'C2H50H'L / 2C2H2O4: C, 68.87; H, 8.67; N, 3.35.

Found: C, 68.76; H, 8.81; N, 3.31.

Example 3

Separation of (±) -N-cyclopropylmethyl-3-hydroxy-143-methyl-8-oxamorphiane in the left and right-hand isomers (l-15c and d-15c) A. A solution of 3.37 g ( 10.8 mmol) of the racemic free base 15c obtained according to Example 1 in 30 ml of acetone was added to a boiling solution of 4.06 g (10.9 mmol) of dibenzoyl-d-tartaric acid in 40 ml of methanol and the resulting solution obtained allowed to stand at 20-25 ° C for crystallization. The solid thus obtained was recrystallized 3 times from isopropanol to give 1.50 g of salt [A]. The mother liquor was evaporated to dryness and the residue treated with aqueous ammonia to give 2.19 g of material [B]. The dibenzoyl tartrate [Λ]: [a] D «-79 (D, 0.274; i-propanol), mp 159-61 °.

The base was released with aqueous ammonia to give 0.97 g of the 1 isomer (l-15c); [α] = -74 (C, 0.294; methanol). The free base is dissolved in methanol and treated with HCl in ether to leave, at 0 ° C, 0.98 g of the hydrochloride; mp 281-3 ° C. [α] β = -73 ° (C, 0.300; methanol).

Analysis calculated for C20H27NO2.HCl: C, 68.65; H, .8,06; N, 4.00.

Found: C, 68.82; H, 8.21; N, 3.85.

B. The free base [R] 2.19 g (7.0 mmol) was dissolved in 25 ml of acetone and added to a boiling solution nf 2.64 q (7.0 mmol) of dibenzoyl-1-tartaric acid. The dibenzoyl tartrate, which crystallized on standing at 20-25 ° C, was recrystallized three times from i-propanol to give 2.32 g of solid, mp 153-4 ° of the d isomer (d-15 cJ).

[α] = +74 (C 0.200; i-propanol).

The free base was released with aqueous ammonia to give 0.97 g of material.

[.alpha.] D @ 20 = +72 (C, 0.238; methanol).

The free base was dissolved in methanol and treated with a solution of HCl in ether to give 0.93 g of the hydrochloride, mp 283-5 °.

[α] = +74 (C, 0.224; methanol).

K o ·

All temperatures are expressed in C.

Claims (1)

145Λ64 1. 8-oxamorphinan derivatives for use as intermediates for the preparation of N-substituted 3-hydroxy-8-oxamorphinans of the general formula: R6 wherein R · is "- R6 or -CH₂- or CH 2, and R represents H or alkyl of 1-6 carbon atoms, or pharmaceutically useful acid addition salts thereof, characterized in that they have the general formula: [01 / & (II>! / k) 23 where R represents alkyl with 1-6 carbon atoms and R represents H or alkyl of 1-6 carbon atoms or are acid addition salts thereof 2. 8-oxamorphinane derivatives according to claim 1, characterized in that they have the formula ^ L - H H'-O ^ T '0 Ό